China Inflation Misses Forecast as Consumer Spending Stays Weak, Producer Prices Surge 
Asian Currencies Mixed as Dollar Slips on Iran Peace Hopes and Fed Rate Outlook 
Kremlin Says New EU Sanctions Won’t Hurt Russian Banks 
Intesa Sanpaolo Launches €30.6 Billion Bid for Monte dei Paschi to Drive Italian Banking Consolidation 
Japan Producer Prices Surge in May, Strengthening Expectations of BOJ Rate Hike 
Asian Stocks Rally as Trump Signals Iran Peace Deal; Tech and Chip Shares Rebound Strongly 
Asian Stocks Slide as Tech Selloff Deepens and US-Iran Conflict Escalates 
GM and Peak Energy Partner to Advance Sodium-Ion Battery Technology for Grid Storage 
Trump Signals Possible U.S.-Iran Peace Deal as Hormuz Reopening Nears 
Apple Unveils Enhanced Apple Intelligence and Next-Generation Siri at WWDC 2026 
ECB Keeps July Rate Options Open Amid Iran War Energy Price Risks 
South Korea Signals Possible Interest Rate Hike as Inflation Remains Elevated 
OpenAI Eyes Massive 10GW Ohio Data Center Campus in Potential $500 Billion AI Infrastructure Deal 
ECB Set to Raise Interest Rates as Energy Shock Fuels Eurozone Inflation Concerns 
Changchun Targets EV Growth as China’s Auto Industry Consolidation Accelerates 
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
